GSK's share price has been hit after a US advisory panel narrowed its recommendations on respiratory syncytial virus (RSV) vaccines, but Moderna could be the biggest loser after waning efficacy data was revealed.
Moderna And GSK Hit By Declining RSV Vaccines Expectations
The efficacy of Moderna’s jab appears to fade faster than its rivals, while experts were surprised by an FDA panel’s recommendation to narrow the use of all three RSV vaccines.
